Zobrazeno 1 - 10
of 196
pro vyhledávání: '"André Pèlegrin"'
Autor:
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge, Thierry Chardès
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity.
Externí odkaz:
https://doaj.org/article/8a10b603d78a414f85898e71f788257b
Autor:
Maëva Chauvin, Véronique Garambois, Pierre-Emmanuel Colombo, Myriam Chentouf, Laurent Gros, Jean-Paul Brouillet, Bruno Robert, Marta Jarlier, Karen Dumas, Pierre Martineau, Isabelle Navarro-Teulon, David Pépin, Thierry Chardès, André Pèlegrin
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract In ovarian carcinoma, anti-Müllerian hormone (AMH) type II receptor (AMHRII) and the AMH/AMHRII signaling pathway are potential therapeutic targets. Here, AMH dose-dependent effect on signaling and proliferation was analyzed in four ovarian
Externí odkaz:
https://doaj.org/article/3bb1d01d694a4347845bf86dc683698e
Autor:
Jérôme Lacombe, Muriel Brengues, Alain Mangé, Céline Bourgier, Sophie Gourgou, André Pèlegrin, Mahmut Ozsahin, Jérôme Solassol, David Azria
Publikováno v:
Radiation Oncology, Vol 14, Iss 1, Pp 1-11 (2019)
Abstract Background Biomarkers for predicting late normal tissue toxicity to radiotherapy are necessary to personalize treatments and to optimize clinical benefit. Many radiogenomic studies have been published on this topic. Conversely, proteomics ap
Externí odkaz:
https://doaj.org/article/6467dd72a28346129ffe48e7196fef29
Autor:
Christophe Le Clorennec, Yassamine Lazrek, Olivier Dubreuil, Carla Sampaio, Christel Larbouret, Romain Lanotte, Marie-Alix Poul, Jean-Marc Barret, Jean-François Prost, André Pèlegrin, Thierry Chardès
Publikováno v:
Cell Communication and Signaling, Vol 17, Iss 1, Pp 1-16 (2019)
Abstract Background HER3/ErbB3 receptor deletion or blockade leads to tumor cell apoptosis, whereas its overexpression confers anti-cancer drug resistance through upregulation of protective mechanisms against apoptosis. We produced the anti-HER3 anti
Externí odkaz:
https://doaj.org/article/4b70fcb461494809aa475152be331389
Autor:
Yahya Ashraf, Hanane Mansouri, Valérie Laurent-Matha, Lindsay B. Alcaraz, Pascal Roger, Séverine Guiu, Danielle Derocq, Gautier Robin, Henri-Alexandre Michaud, Helène Delpech, Marta Jarlier, Martine Pugnière, Bruno Robert, Anthony Puel, Lucie Martin, Flavie Landomiel, Thomas Bourquard, Oussama Achour, Ingrid Fruitier-Arnaudin, Alexandre Pichard, Emmanuel Deshayes, Andrei Turtoi, Anne Poupon, Joëlle Simony-Lafontaine, Florence Boissière-Michot, Nelly Pirot, Florence Bernex, William Jacot, Stanislas du Manoir, Charles Theillet, Jean-Pierre Pouget, Isabelle Navarro-Teulon, Nathalie Bonnefoy, André Pèlegrin, Thierry Chardès, Pierre Martineau, Emmanuelle Liaudet-Coopman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-17 (2019)
Abstract Background Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as a
Externí odkaz:
https://doaj.org/article/29cfb2cf1cb546cb9c2f21a1f397c343
Autor:
Bérénice Framery, Marian Gutowski, Karen Dumas, Alexandre Evrard, Nathalie Muller, Vincent Dubois, Jérôme Quinonero, François Scherninski, André Pèlegrin, Françoise Cailler
Publikováno v:
Toxicology Reports, Vol 6, Iss , Pp 409-415 (2019)
The real-time improvement of the intraoperative discrimination between different tissue types (particularly between tumor and adjacent normal tissue) using intraoperative imaging represents a considerable advance for oncology surgeons. However, the d
Externí odkaz:
https://doaj.org/article/c73e0e9844304d9397132dc4f5b5b56e
Autor:
Emilia Rabia, Véronique Garambois, Julie Hubert, Marine Bruciamacchie, Nelly Pirot, Hélène Delpech, Morgane Broyon, Charles Theillet, Pierre-Emmanuel Colombo, Nadia Vie, Diego Tosi, Celine Gongora, Lakhdar Khellaf, Marta Jarlier, Nina Radosevic-Robin, Thierry Chardès, André Pèlegrin, Christel Larbouret
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Chemoresistance, particularly to gemcitabine, is a major challenge in pancreatic cancer. The epidermal growth factor receptor (EGFR) and human epidermal growth factor receptors 2 and 3 (HER2, HER3) are expressed in many tumors, and they are relevant
Externí odkaz:
https://doaj.org/article/321dae94e99e49a6a55ffcb4d608277f
Autor:
David Azria, Olivier Riou, Florence Castan, Tan Dat Nguyen, Karine Peignaux, Claire Lemanski, Jean-Léon Lagrange, Youlia Kirova, Eric Lartigau, Yazid Belkacemi, Céline Bourgier, Sofia Rivera, Georges Noël, Sébastien Clippe, Françoise Mornex, Christophe Hennequin, Andrew Kramar, Sophie Gourgou, André Pèlegrin, Pascal Fenoglietto, Esat Mahmut Ozsahin
Publikováno v:
EBioMedicine, Vol 2, Iss 12, Pp 1965-1973 (2015)
Background: Monocentric cohorts suggested that radiation-induced CD8 T-lymphocyte apoptosis (RILA) can predict late toxicity after curative intent radiotherapy (RT). We assessed the role of RILA as a predictor of breast fibrosis (bf+) after adjuvant
Externí odkaz:
https://doaj.org/article/998b692f296349d7954dcffe6dcf535a
Autor:
Yassamine Lazrek, Olivier Dubreuil, Véronique Garambois, Nadège Gaborit, Christel Larbouret, Christophe Le Clorennec, Gaelle Thomas, Wilhem Leconet, Marta Jarlier, Martine Pugnière, Nadia Vié, Bruno Robert, Céline Monnet, Khalil Bouayadi, Hakim Kharrat, Philippe Mondon, André Pèlegrin, Thierry Chardès
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 15, Iss 3, Pp 335-347 (2013)
Blockade of the human epidermal growth factor receptor 3 (HER3) and of the downstream phosphatidylinositide 3-kinase (PI3K)/AKT pathway is a prerequisite for overcoming drug resistance and to develop novel treatments for cancers that are not eligible
Externí odkaz:
https://doaj.org/article/b4bb9ea6da264287898535708be0be8f
Autor:
Christel Larbouret, Nadège Gaborit, Thierry Chardès, Mickaël Coelho, Emmanuelle Campigna, Caroline Bascoul-Mollevi, Jean-Pierre Mach, David Azria, Bruno Robert, André Pèlegrin
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 14, Iss 2, Pp 121-130 (2012)
We previously demonstrated the synergistic therapeutic effect of the cetuximab (anti-epidermal growth factor receptor [EGFR] monoclonal antibody, mAb)-trastuzumab (anti-HER2 mAb) combination (2mAbs therapy) in HER2low human pancreatic carcinoma xenog
Externí odkaz:
https://doaj.org/article/df911cfa8d0242e398f9e0c7cae97c67